Our findings reveal the molecular rationale for combining MEK inhibitors with PD-L1 blockade, identify the mechanism of combinatorial drug resistance, identify potential predictive markers of immunotherapy response, and validate a promising triple combinatorial treatment strategy for patients with KRAS mutant lung cancer. The gene discussed is KRAS; the disease is lung cancer.